Retatrutide
Three receptors. One molecule. A new conversation with metabolism.
Includes syringes & alcohol pads
HPLC-verified ≥99% purity · Certificate of Analysis
The triple agonist at the edge of metabolic research.
Retatrutide represents the current frontier of metabolic peptide research — a single molecule engineered to activate three receptors: GLP-1, GIP, and glucagon. Where its predecessors influenced appetite and insulin, retatrutide adds a glucagon dimension that modulates energy expenditure itself.
It is investigational and remains under active study. For those examining the outer edge of metabolic regulation, it is the compound the research field is watching most closely.
Appetite Regulation
GLP-1 activation supports satiety signaling and glucose-dependent insulin release.
Energy Balance
The glucagon component influences metabolic rate and energy expenditure.
Body Composition
Researched for effects on fat mass and metabolic flexibility.
Glycemic Response
GIP contribution supports insulin sensitivity and post-meal glucose handling.
Background
Retatrutide is investigational and represents the current frontier of triple-receptor metabolic peptide research, with a growing body of literature on its three-receptor mechanism.
Often paired with:
Questions, answered.
"The edge of the research is quiet, careful work. This is where it lives."
Tirzepatide
The dual-agonist that redefined metabolic regulation.
NAD+
The current beneath every cellular conversation.
MOTS-C
The signal your mitochondria send to the rest of you.
For research use only. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
Research peptides are short chains of amino acids used exclusively for scientific research and laboratory studies. They are not intended for human consumption, diagnostic, or therapeutic use.